Lipidoid Tail Structure Strongly Influences siRNA Delivery Activity
- 537 Downloads
RNA interference therapeutics have been limited, in large part, by the lack of efficient, non-toxic, non-immunogenic delivery systems. Among previously established methods, lipidoid nanoparticles (LNPs) show particular promise in delivering siRNA to diverse cell and organ targets in vitro and in vivo. However, a better understanding of structure–function relationships is needed to facilitate broad translation to clinical applications. Here, we demonstrate the critical role of tail chemistry in conferring delivery efficacy to lipidoid molecules with three or four aliphatic tails. Tail length and structure significantly affected siRNA transfection in HeLa cells, with methacrylate (vs. acrylate) tails and tails containing ethers causing reductions in efficacy. Notably, we report a novel tail precursor, isodecyl acrylate, that conveyed marked siRNA delivery ability in vitro and in vivo. LNPs with isodecyl acrylate lipidoids uniformly induced greater than 90% gene silencing, both in vitro and in mice (hepatocytes), at 40 nM and 0.1 mg/kg, respectively. Furthermore, we found that tail chemistry significantly influenced the surface pKa values of formulated LNPs, with tails that conferred higher pKa facilitating higher levels of gene knockdown. Together, these data underscore the importance of lipidoid tail structure and provide guidance for the development of next generation lipid nanoparticle siRNA delivery systems.
KeywordsLipid nanoparticles siRNA delivery Nanomedicine Hepatocellular delivery RNA interference Structure–function
Conflict of interest
Christopher M. Knapp, Penghong Guo, and Kathryn A. Whitehead declare that they have no conflicts of interest.
Funding was provided by Carnegie Mellon University and the DSF Charitable Foundation.
Research Involved in Human and Animal Rights
No human studies were carried out by the authors for this article. All institutional and national guidelines for the care and use of laboratory animals were followed and approved by the Carnegie Mellon University Institutional Animal Care and Use Committee.
- 1.Akinc, A., W. Querbes, S. De, J. Qin, M. Frank-Kamenetsky, K. N. Jayaprakash, M. Jayaraman, K. G. Rajeev, W. L. Cantley, J. R. Dorkin, J. S. Butler, L. Qin, T. Racie, A. Sprague, E. Fava, A. Zeigerer, M. J. Hope, M. Zerial, D. W. Sah, K. Fitzgerald, M. A. Tracy, M. Manoharan, V. Koteliansky, A. de Fougerolles, and M. A. Maier. Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms. Mol. Ther. 18:1357–1364, 2010.CrossRefGoogle Scholar
- 2.Akinc, A., A. Zumbuehl, M. Goldberg, E. S. Leshchiner, V. Busini, N. Hossain, S. A. Bacallado, D. N. Nguyen, J. Fuller, R. Alvarez, A. Borodovsky, T. Borland, R. Constien, A. De Fougerolles, J. R. Dorkin, K. Narayanannair Jayaprakash, M. Jayaraman, M. John, V. Koteliansky, M. Manoharan, L. Nechev, J. Qin, T. Racie, D. Raitcheva, K. G. Rajeev, D. W. Y. Sah, J. Soutschek, I. Toudjarska, H. Vornlocher, T. S. Zimmermann, R. Langer, and D. G. Anderson. A combinatorial library of lipid-like materials for delivery of RNAi therapeutics. Nat. Biotechnol. 26:561–569, 2008.CrossRefGoogle Scholar
- 5.Chen, C.-K., W.-C. Law, R. Aalinkeel, B. Nair, A. Kopwitthaya, S. D. Mahajan, J. L. Reynolds, J. Zou, S. A. Schwartz, P. N. Prasad, and C. Cheng. Well-defined degradable cationic polylactide as nanocarrier for the delivery of siRNA to silence angiogenesis in prostate cancer. Adv. Healthc. Mater. 1:751–761, 2012.CrossRefGoogle Scholar
- 6.Dong, Y., K. T. Love, J. R. Dorkin, S. Sirirungruang, Y. Zhang, D. Chen, R. L. Bogorad, H. Yin, Y. Chen, A. J. Vegas, C. A. Alabi, G. Sahay, K. T. Olejnik, W. Wang, A. Schroeder, A. K. R. Lytton-Jean, D. J. Siegwart, A. Akinc, C. Barnes, S. A. Barros, M. Carioto, K. Fitzgerald, J. Hettinger, V. Kumar, T. I. Novobrantseva, J. Qin, W. Querbes, V. Koteliansky, R. Langer, and D. G. Anderson. Lipopeptide nanoparticles for potent and selective siRNA delivery in rodents and nonhuman primates. Proc. Natl. Acad. Sci. 111:3955–3960, 2014.CrossRefGoogle Scholar
- 8.Fitzgerald, K., M. Frank-Kamenetsky, S. Shulga-Morskaya, A. Liebow, B. R. Bettencourt, J. E. Sutherland, R. M. Hutabarat, V. A. Clausen, V. Karsten, J. Cehelsky, S. V. Nochur, V. Kotelianski, J. Horton, T. Mant, J. Chiesa, J. Ritter, M. Munisamy, A. K. Vaishnaw, J. A. Gollob, and A. Simon. Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial. Lancet 383:60–68, 2014.CrossRefGoogle Scholar
- 9.Frank-Kamenetsky, M., A. Grefhorst, N. N. Anderson, T. S. Racie, B. Bramlage, A. Akinc, D. Butler, K. Charisse, R. Dorkin, Y. Fan, C. Gamba-Vitalo, P. Hadwiger, M. Jayaraman, M. John, K. N. Jayaprakash, M. Maier, L. Nechev, K. G. Rajeev, T. Read, I. Röhl, J. Soutschek, P. Tan, J. Wong, G. Wang, T. Zimmermann, A. de Fougerolles, H.-P. Vornlocher, R. Langer, D. G. Anderson, M. Manoharan, V. Koteliansky, J. D. Horton, and K. Fitzgerald. Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates. Proc. Natl. Acad. Sci. 105:11915–11920, 2008.CrossRefGoogle Scholar
- 10.Gilleron, J., W. Querbes, A. Zeigerer, A. Borodovsky, G. Marsico, U. Schubert, K. Manygoats, S. Seifert, C. Andree, M. Stöter, H. Epstein-Barash, L. Zhang, V. Koteliansky, K. Fitzgerald, E. Fava, M. Bickle, Y. Kalaidzidis, A. Akinc, M. Maier, and M. Zerial. Image-based analysis of lipid nanoparticle-mediated siRNA delivery, intracellular trafficking and endosomal escape. Nat. Biotechnol. 31:638–646, 2013.CrossRefGoogle Scholar
- 12.Jayaraman, M., S. M. Ansell, B. L. Mui, Y. K. Tam, J. Chen, X. Du, D. Butler, L. Eltepu, S. Matsuda, J. K. Narayanannair, K. G. Rajeev, I. M. Hafez, A. Akinc, M. A. Maier, M. A. Tracy, P. R. Cullis, T. D. Madden, M. Manoharan, and M. J. Hope. Maximizing the potency of siRNA lipid nanoparticles for hepatic gene silencing in vivo. Angew. Chem. Int. Ed. 51:8529–8533, 2012.CrossRefGoogle Scholar
- 13.Kumar, V., J. Qin, Y. Jiang, R. G. Duncan, B. Brigham, S. Fishman, J. K. Nair, A. Akinc, S. A. Barros, and P. V. Kasperkovitz. Shielding of lipid nanoparticles for siRNA delivery: impact on physicochemical properties, cytokine induction, and efficacy. Mol. Ther. Nucl. Acids 3:e210, 2014.CrossRefGoogle Scholar
- 14.Love, K. T., K. P. Mahon, C. G. Levins, K. A. Whitehead, W. Querbes, J. R. Dorkin, J. Qin, W. Cantley, L. L. Qin, T. Racie, M. Frank-Kamenetsky, K. N. Yip, R. Alvarez, D. W. Y. Sah, A. de Fougerolles, K. Fitzgerald, V. Koteliansky, A. Akinc, R. Langer, and D. G. Anderson. Lipid-like materials for low-dose, in vivo gene silencing. Proc. Natl. Acad. Sci. 107:1864–1869, 2010.CrossRefGoogle Scholar
- 17.Sahay, G., W. Querbes, C. Alabi, A. Eltoukhy, S. Sarkar, C. Zurenko, E. Karagiannis, K. Love, D. Chen, R. Zoncu, Y. Buganim, A. Schroeder, R. Langer, and D. G. Anderson. Efficiency of siRNA delivery by lipid nanoparticles is limited by endocytic recycling. Nat. Biotechnol. 31:653–658, 2013.CrossRefGoogle Scholar
- 18.Sehgal, A., S. Barros, L. Ivanciu, B. Cooley, J. Qin, T. Racie, J. Hettinger, M. Carioto, Y. Jiang, J. Brodsky, H. Prabhala, X. Zhang, H. Attarwala, R. Hutabarat, D. Foster, S. Milstein, K. Charisse, S. Kuchimanchi, M. A. Maier, L. Nechev, P. Kandasamy, A. V. Kel’in, J. K. Nair, K. G. Rajeev, M. Manoharan, R. Meyers, B. Sorensen, A. R. Simon, Y. Dargaud, C. Negrier, R. M. Camire, and A. Akinc. An RNAi therapeutic targeting antithrombin to rebalance the coagulation system and promote hemostasis in hemophilia. Nat. Med. 21:492–497, 2015.CrossRefGoogle Scholar
- 19.Semple, S. C., A. Akinc, J. Chen, A. P. Sandhu, B. L. Mui, C. K. Cho, D. W. Y. Sah, D. Stebbing, E. J. Crosley, E. Yaworski, I. M. Hafez, J. R. Dorkin, J. Qin, K. Lam, K. G. Rajeev, K. F. Wong, L. B. Jeffs, L. Nechev, M. L. Eisenhardt, M. Jayaraman, M. Kazem, M. A. Maier, M. Srinivasulu, M. J. Weinstein, Q. Chen, R. Alvarez, S. A. Barros, S. De, S. K. Klimuk, T. Borland, V. Kosovrasti, W. L. Cantley, Y. K. Tam, M. Manoharan, M. A. Ciufolini, M. A. Tracy, A. de Fougerolles, I. MacLachlan, P. R. Cullis, T. D. Madden, and M. J. Hope. Rational design of cationic lipids for siRNA delivery. Nat. Biotechnol. 28:172–176, 2010.CrossRefGoogle Scholar
- 21.Whitehead, K.A., J.R. Dorkin, A.J. Vegas, P.H. Chang, O. Veiseh, J. Matthews, O.S. Fenton, Y. Zhang, K.T. Olejnik, V. Yesilyurt, D. Chen, S. Barros, B. Klebanov, T. Novobrantseva, R. Langer, and D.G. Anderson. Degradable lipid nanoparticles with predictable in vivo siRNA delivery activity. Nat. Commun. 5, 2014 [cited 2014 Oct 7]. Available from: http://www.nature.com/ncomms/2014/140627/ncomms5277/full/ncomms5277.html.
- 26.Wooddell, C. I., D. B. Rozema, M. Hossbach, M. John, H. L. Hamilton, Q. Chu, J. O. Hegge, J. J. Klein, D. H. Wakefield, C. E. Oropeza, J. Deckert, I. Roehl, K. Jahn-Hofmann, P. Hadwiger, H.-P. Vornlocher, A. McLachlan, and D. L. Lewis. Hepatocyte-targeted RNAi therapeutics for the treatment of chronic hepatitis B virus infection. Mol. Ther. 21:973–985, 2013.CrossRefGoogle Scholar